Vagus nerve stimulation (VNS) for treatment-resistant depression has followed an unusual trajectory: FDA-approved since 2005, cautiously adopted, and still generating controversy two decades later. The RECOVER trial — the largest sham-controlled VNS study for depression ever conducted — delivered mixed headlines when its primary endpoint fell short, but its long-term durability data told a more compelling story. Understanding both the device technology and the trial results is essential for anyone considering VNS for depression or evaluating it for a patient.
How Implanted VNS Works
The standard VNS system consists of a pulse generator implanted beneath the skin of the left chest wall (below the clavicle), connected by a lead wire to the left cervical vagus nerve. The generator delivers intermittent electrical pulses — typically 30 seconds on, five minutes off — that travel along vagal afferent fibres to the nucleus tractus solitarius (NTS) in the brainstem. From the NTS, signals propagate to the locus coeruleus, the dorsal raphe nucleus and limbic structures including the amygdala and prefrontal cortex.
The antidepressant mechanism is not fully understood, but the leading hypothesis centres on modulation of monoamine neurotransmission. The locus coeruleus is the brain’s primary source of norepinephrine, and the dorsal raphe is the principal source of serotonin — the same two neurotransmitters targeted by most antidepressant medications. VNS appears to enhance the tonic firing rates of these nuclei rather than blocking reuptake, which may explain why its clinical profile differs from that of conventional antidepressants: slower onset but potentially more durable response.
The RECOVER Trial: What It Found
The RECOVER trial, published in 2026 in the International Journal of Neuropsychopharmacology, enrolled approximately 500 patients across 84 sites in the United States. These were not mildly depressed individuals — participants had failed an average of 13 prior treatments, including medications, psychotherapy and often electroconvulsive therapy. This is the most treatment-resistant population ever studied in a VNS trial.
The primary endpoint — change in Montgomery-Asberg Depression Rating Scale (MADRS) scores versus sham stimulation over the acute treatment phase — did not reach statistical significance. This result generated headlines suggesting VNS had “failed” for depression. However, the trial’s long-term open-label data painted a different picture.
At 12 months, 69% of patients who continued VNS met criteria for clinical response. At 24 months, over 80% of responders maintained their improvement. Among those who achieved strong initial responses, 92% sustained their benefit at two years. Remission rates — meaning patients whose depression essentially resolved — exceeded 20% at the 24-month mark. For a population averaging 13 prior treatment failures, these durability numbers are remarkable.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Why the Primary Endpoint Missed
The discrepancy between the negative primary endpoint and the strong long-term results likely reflects VNS’s slow onset of action. Unlike antidepressant medications that can show effects within weeks, VNS-mediated changes in brainstem neurotransmitter systems may require months of continuous stimulation to produce clinically meaningful improvement. The acute sham-controlled phase may simply have been too short to capture the treatment effect in this exceptionally resistant population.
Additionally, high placebo response rates in VNS trials — patients know they had surgery and have a device in their chest — may compress the between-group difference even when both groups are improving. The long-term durability data, where patients serve as their own controls over time, may be a more informative measure for a neuromodulatory treatment with a slow mechanism of action.
VNS vs Other Neuromodulation
VNS occupies a specific niche among neuromodulation treatments for depression. Transcranial magnetic stimulation (TMS) targets cortical regions directly and is typically used for moderate treatment resistance (one to three failed medications). Electroconvulsive therapy (ECT) remains the most acutely effective treatment for severe depression but requires repeated anaesthesia sessions, can cause memory side effects and has high relapse rates after discontinuation. Deep brain stimulation (DBS) is investigational for depression and involves electrodes placed directly in brain structures.
VNS’s distinguishing feature is its durability. The device operates continuously — it does not require the patient to attend repeated sessions or maintain a treatment schedule. Once implanted and calibrated, it delivers stimulation around the clock. The RECOVER data suggesting that 80% or more of responders maintain their improvement at 24 months compares favourably with the high relapse rates seen after ECT or TMS discontinuation. For the most treatment-resistant patients — those who have exhausted other options — this sustained effect represents a meaningful advantage.
Transcutaneous VNS for Depression
Transcutaneous vagus nerve stimulation (taVNS) — non-invasive stimulation through the skin of the ear, targeting the auricular branch of the vagus nerve (ABVN) in the cymba conchae — has been investigated for depression as a lower-risk alternative to implanted VNS. Peuker and Filler’s 2002 dissection study confirmed that the cymba conchae receives 100% of its sensory innervation from the ABVN, making it the optimal auricular stimulation target.
Several small trials have shown promising results for taVNS in depression, with improvements in depressive symptom scores compared to sham stimulation. However, the evidence base is substantially smaller and less rigorous than for implanted VNS. Whether taVNS can match implanted VNS for the most treatment-resistant patients — the population where implanted VNS shows its strongest long-term results — remains unknown. The two approaches may ultimately serve different severity levels: taVNS as an accessible adjunctive treatment for moderate depression, implanted VNS for the most refractory cases.
Side Effects and Practical Considerations
Implanted VNS surgery carries the standard risks of any procedure requiring general anaesthesia and involves placing hardware around a major nerve. The most common side effects are voice alteration and hoarseness during stimulation (the recurrent laryngeal nerve, a vagal branch controlling the vocal cords, is affected by the electrical current), coughing, shortness of breath during stimulation, and neck discomfort. A 2022 systematic review found that serious adverse events from VNS are extremely rare; the common side effects are generally mild, tend to improve with parameter adjustment and often diminish over time.
The device battery lasts several years and requires surgical replacement when depleted — a minor outpatient procedure, but a practical consideration for long-term treatment planning. Implanted VNS is not compatible with some MRI protocols, which may limit future diagnostic imaging options.
Who Should Consider VNS for Depression
Based on the RECOVER trial population and existing clinical guidelines, implanted VNS for depression is appropriate for adults with chronic or recurrent major depressive disorder who have failed multiple adequate medication trials and at least one course of psychotherapy. It is not a first-line treatment — its value lies specifically in the treatment-resistant population where conventional approaches have been exhausted. The RECOVER data’s 20% remission rate at 24 months and 80% maintenance of response may not sound dramatic in isolation, but for patients averaging 13 prior treatment failures, these represent outcomes that no other available treatment reliably delivers.
Depression is one of many conditions where the vagus nerve plays a central role. To understand how this single nerve connects your brain to your immune system, your heart and your gut — and why that matters for mental health — get the Vagus Nerve & Me eBook.
